UniQure PE Ratio 2013-2022 | QURE
Current and historical p/e ratio for UniQure (QURE) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. UniQure PE ratio as of February 03, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| UniQure PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
22.52 |
|
0.00 |
| 2022-09-30 |
18.76 |
$-2.69 |
0.00 |
| 2022-06-30 |
18.64 |
$-2.46 |
0.00 |
| 2022-03-31 |
18.07 |
$6.89 |
2.62 |
| 2021-12-31 |
20.74 |
$6.98 |
2.97 |
| 2021-09-30 |
32.01 |
$6.80 |
4.71 |
| 2021-06-30 |
30.80 |
$6.38 |
4.83 |
| 2021-03-31 |
33.69 |
$-3.09 |
0.00 |
| 2020-12-31 |
36.13 |
$-2.81 |
0.00 |
| 2020-09-30 |
36.83 |
$-3.77 |
0.00 |
| 2020-06-30 |
45.06 |
$-3.14 |
0.00 |
| 2020-03-31 |
47.45 |
$-3.01 |
0.00 |
| 2019-12-31 |
71.66 |
$-3.12 |
0.00 |
| 2019-09-30 |
39.36 |
$-2.74 |
0.00 |
| 2019-06-30 |
78.15 |
$-2.75 |
0.00 |
| 2019-03-31 |
59.65 |
$-2.49 |
0.00 |
| 2018-12-31 |
28.82 |
$-2.34 |
0.00 |
| 2018-09-30 |
36.39 |
$-2.66 |
0.00 |
| 2018-06-30 |
37.80 |
$-2.47 |
0.00 |
| 2018-03-31 |
23.50 |
$-2.73 |
0.00 |
| 2017-12-31 |
19.59 |
$-2.94 |
0.00 |
| 2017-09-30 |
9.60 |
$-2.61 |
0.00 |
| 2017-06-30 |
6.19 |
$-2.81 |
0.00 |
| 2017-03-31 |
5.78 |
$-2.96 |
0.00 |
| 2016-12-31 |
5.60 |
$-3.08 |
0.00 |
| 2016-09-30 |
7.65 |
$-3.14 |
0.00 |
| 2016-06-30 |
7.37 |
$-3.74 |
0.00 |
| 2016-03-31 |
11.88 |
$-2.76 |
0.00 |
| 2015-12-31 |
16.54 |
$-2.47 |
0.00 |
| 2015-09-30 |
20.45 |
$-2.50 |
0.00 |
| 2014-12-31 |
14.81 |
$-2.01 |
0.00 |
| 2014-09-30 |
9.25 |
$-2.97 |
0.00 |
| 2014-06-30 |
13.59 |
$-3.09 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.054B |
$0.524B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
